Schwartz A B, Shapiro W A, Suave M J, Shen E, Bhandari A, Morady F, Scheinman M
Can J Cardiol. 1987 Mar;3(2):75-82.
Electrophysiologic studies were performed in 6 consecutive patients with bundle branch block and organic heart disease. All were studied after intravenous (0.9 mg/kg) encainide and 3 of the 6 after 36-72 hours of oral encainide (50 mg every 6 hours). After intravenous encainide, mean H-Q increased from 51 +/- 20 msec to 58 +/- 25 msec (14% p less than or equal to .05). After oral encainide (3 patients) H-Q increased to 90 +/- 39 msec (56% p less than or equal to .05, compared to baseline). Programmed ventricular stimulation was performed in 5. In 1 patient without spontaneous ventricular tachycardia, tachycardia was non-inducible before and after encainide. Of 5 patients with spontaneous arrhythmia, 3 had ventricular tachycardia induced before and after intravenous encainide at mean cycle lengths of 287 +/- 130 msec and 407 +/- 261 msec, (not significant) respectively, while 1 had ventricular tachycardia induced only after encainide. Four patients began chronic treatment with oral encainide (2 patients with inducible rapid ventricular tachycardia after encainide were excluded). All suffered major adverse outcomes. One died suddenly after an electrophysiology study demonstrated inducible ventricular tachycardia, which occurred only after encainide. One experienced new syncope after baseline H-Q increased 75% after encainide. Two patients developed new sustained atrial tachycardias and 1 patient developed persistent ventricular tachycardia on encainide.(ABSTRACT TRUNCATED AT 250 WORDS)
对6例连续的束支传导阻滞合并器质性心脏病患者进行了电生理研究。所有患者均在静脉注射(0.9mg/kg)恩卡尼后接受研究,6例中的3例在口服恩卡尼(每6小时50mg)36 - 72小时后接受研究。静脉注射恩卡尼后,平均H-Q间期从51±20毫秒增加到58±25毫秒(增加14%,p≤0.05)。口服恩卡尼后(3例患者),H-Q间期增加到90±39毫秒(增加56%,与基线相比p≤0.05)。对5例患者进行了程控心室刺激。1例无自发性室性心动过速的患者,在恩卡尼给药前后均不能诱发心动过速。5例有自发性心律失常的患者中,3例在静脉注射恩卡尼前后分别诱发室性心动过速,平均周期长度分别为287±130毫秒和407±261毫秒(无显著性差异),而1例仅在恩卡尼给药后诱发室性心动过速。4例患者开始口服恩卡尼进行长期治疗(排除2例在恩卡尼给药后可诱发快速室性心动过速的患者)。所有患者均出现严重不良后果。1例在电生理研究显示仅在恩卡尼给药后可诱发室性心动过速后突然死亡。1例在基线H-Q间期在恩卡尼给药后增加75%后出现新的晕厥。2例患者出现新的持续性房性心动过速,1例患者在服用恩卡尼时出现持续性室性心动过速。(摘要截选至250字)